Shifting China OTC Sales Affect J&J, Prompt New Alliances
This article was originally published in PharmAsia News
Executive Summary
Johnson & Johnson sees shifting consumer behavior in China as a reason for its slowing OTC sales in this market, a trend that could potentially force more multinationals to embrace the e-commerce phenomenon. Pfizer is among the first such companies to form a tie-up with a domestic firm to surf the surging online drug sales tide.